SABS trades 273.9% below Wall Street's consensus target of $11.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SABS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, SAB Biotherapeutics, Inc. (SABS) has a Wall Street consensus price target of $11.33, based on estimates from 8 covering analysts. With the stock currently trading at $3.03, this represents a potential upside of +273.9%. The company has a market capitalization of $283M.
Analyst price targets range from a low of $10.00 to a high of $13.00, representing a 26% spread in expectations. The median target of $11.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SABS trades at a trailing P/E of -3.5x. Analysts expect EPS to grow -657.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 ARGXargenx SE | $60.2B | $927.21 | $1133.33 | +22.2% | Buy | 32.6x | 36 |
 HALOHalozyme Therapeutics, Inc. | $12.3B | $103.63 | $110.00 | +6.1% | Buy | 12.0x | 27 |
 ADMAADMA Biologics, Inc. | $3.0B | $12.73 | $19.00 | +49.3% | Buy | 16.0x | 10 |
 CRVSCorvus Pharmaceuticals, Inc. | $886M | $10.54 | $27.00 | +156.2% | Buy | — | 13 |
 VXRTVaxart, Inc. | $90M | $0.37 | $2.00 | +440.5% | Buy | 1.2x | 3 |
 NVAXNovavax, Inc. | $1.8B | $10.78 | $18.00 | +67.0% | Buy | — | 23 |
 DYAIDyadic International, Inc. | $12M | $0.34 | — | — | — | — | — |
 BNTXBioNTech SE | $22.0B | $87.51 | $120.33 | +37.5% | Buy | — | 24 |
 ABCLAbCellera Biologics Inc. | $3.6B | $11.88 | $18.20 | +53.2% | Buy | — | 12 |
Quick answers to the most common questions about buying SABS stock.
The consensus Wall Street price target for SABS is $11.33, representing 273.9% upside from the current price of $3.03. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SABS has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $11.33 implies 273.9% upside from current levels.
SABS's current price is $3.03 with a consensus target of $11.33 (273.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $13 for SABS, while the most conservative target is $10. The consensus of $11.33 represents the median expectation. These targets typically reflect 12-month expectations.
SABS is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SABS stock forecast based on 8 Wall Street analysts shows a consensus price target of $11.33, with estimates ranging from $10 (bear case) to $13 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SABS, with a "Buy" consensus rating and $11.33 price target (273.9% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SABS analyst price targets range from $10 to $13, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11.33 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.